Epygenix is a precision medicine-based biopharmaceutical company discovering and developing drugs that treat Dravet syndrome and other genetic epilepsies.
Location: United States, New Jersey, Paramus
Employees: 1-10
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Proioxis V... | proioxis.v... |
Mentions in press and media 7
| Date | Title | Description |
| 02.05.2024 | Mstone Portfolio Company, Epygenix Therapeutics, Announces Agreement to be Acquired For Total Deal Value of $680M | HONG KONG SAR, May 2, 2024 /EINPresswire.com/ -- Mstone Partners (“Mstone”), an entrepreneurial biotech incubator in the form of a holding company, today announces that Epygenix Therapeutics, Inc. (“Epygenix”), an Mstone portfolio company, ... |
| 28.11.2022 | Epygenix Therapeutics to Present at the American Epilepsy Society 2022 Annual Meeting in Nashville | PARAMUS, NJ, UNITED STATES, November 28, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing therapies for rare and intractable forms of genetic epilepsy, will a... |
| 10.10.2022 | Epygenix Therapeutics to Host Investor Meetings at the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum | PARAMUS, N.J., UNITED STATES, October 10, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing therapies for rare and intractable forms of genetic epilepsy, annou... |
| 17.09.2022 | Epygenix Therapeutics to Present at UBS Biotechnology Virtual Private Company Symposium | PARAMUS, NJ, UNITED STATES, September 17, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing safe, effective and patient-friendly drugs f... |
| 29.06.2022 | Epygenix Therapeutics Receives FDA Orphan Drug Designation for EPX-100 For Treatment of Ohtahara Syndrome | PARAMUS, N.J., UNITED STATES, June 29, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable forms of genetic epilepsy, t... |
| 09.06.2022 | Epygenix Therapeutics to Provide Update at the Dravet Syndrome Foundation (DSF) 2022 Conference | PARAMUS, N.J., UNITED STATES, June 9, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable forms of genetic epilepsy, wi... |
| 20.05.2022 | Epygenix Therapeutics To Participate in UBS Healthcare Virtual 1x1 Day | PARAMUS, NEW JERSEY, UNITED STATES, May 20, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing safe, effective and patient-friendly drugs... |